769966-04-3

Basic information

• Product Name: 7-FLUOROINDOLINE
• Synonyms: 7-FLUOROINDOLINE;AKOS BBV-003106;OTAVA-BB 1118853;7-Fluoro-2,3-dihydro-1H-indole;1H-INDOLE,7-FLUORO-2,3-DIHYDRO-
• CAS NO: 769966-04-3
• Molecular Formula: C₈H₈FN
• Molecular Weight: 137.15
• Mol File: 769966-04-3.mol
• Article Data: 12

Chemical Properties

• Boiling Point: 216.3±29.0 °C(Predicted)
• Appearance: /
• Density: 1.154±0.06 g/cm3(Predicted)
• PKA: 3.90±0.20(Predicted)
• CAS DataBase Reference: 7-FLUOROINDOLINE(CAS DataBase Reference)
• NIST Chemistry Reference: 7-FLUOROINDOLINE(769966-04-3)
• EPA Substance Registry System: 7-FLUOROINDOLINE(769966-04-3)

Safety Data

• Hazardous Substances Data: 769966-04-3(Hazardous Substances Data)

Usage

General Description

7-Fluoroindoline is a chemical compound with the molecular formula C8HA6FN. It is a derivative of indoline with a fluorine atom substituted at the 7th position. 7-Fluoroindoline is a heterocyclic compound with potential applications in pharmaceuticals, agrochemicals, and materials science. It is known for its role as a building block in the synthesis of various biologically active organic compounds and can also be used as a precursor in the production of advanced materials. Additionally, 7-Fluoroindoline has been studied for its potential pharmacological activities, including its anti-inflammatory, antioxidant, and anticancer properties.

Upstream product

• 387-44-0 7-fluoro-1H-indole 

Downstream Products

• 915953-63-8 C₁₉H₂₃N₂F 
• 915953-68-3 C₁₉H₂₂N₂F₂ 
• 915953-72-9 C₁₉H₂₁N₂F 
• 915953-81-0 C₁₈H₁₉FN₂ 
• 954258-03-8 5-bromo-7-fluoroindoline 
• 1359945-95-1 C₂₁H₁₅F₄N₃O₂ 
• 1167055-33-5 7-fluoro-5-nitro-1H-indole 
• 926028-84-4 7-fluoro-1H-indol-5-amine 

Relevant articles and documents

COMPOUND HAVING ERK KINASE INHIBITORY ACTIVITY AND USE THEREOF

The invention relates to a compound of formula (I): wherein variables are as defined in the specification. The compound is an inhibitor of an ERK kinase, e.g. ERK1 and/or ERK2 kinase. The invention also relates to the use of the compound and a method for preparing the compound, and a pharmaceutical composition containing the compound.

5-SULFAMOYL-2-HYDROXYBENZAMIDE DERIVATIVES

The invention is directed to substituted salicylamide derivatives. Specifically, the invention is directed to compounds according to Formula (I): wherein R, R1 and R2 are as defined herein, or a pharmaceutically acceptable salt thereof. The compounds of the invention are inhibitors of CD73 and can be useful in the treatment of cancer, pre-cancerous syndromes and diseases associated with CD73 inhibition, such as AIDS, the treatment of HIV, autoimmune diseases, infections, atherosclerosis, and ischemia–reperfusion injury. Accordingly, the invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to methods of inhibiting CD73 activity and treatment of disorders associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention.

Discovery of a novel series of indoline carbamate and indolinylpyrimidine derivatives as potent GPR119 agonists

GPR119 has emerged as an attractive target for anti-diabetic agents. We identified a structurally novel GPR119 agonist 22c that carries a 5-(methylsulfonyl)indoline motif as an early lead compound. To generate more potent compounds of this series, structural modifications were performed mainly to the central alkylene spacer. Installation of a carbonyl group and a methyl group on this spacer significantly enhanced agonistic activity, resulting in the identification of 2-[1-(5-ethylpyrimidin-2-yl)piperidin-4-yl]propyl 7-fluoro-5-(methylsulfonyl)-2,3-dihydro-1H-indole-1-carboxylate (20). To further expand the chemical series of indoline-based GPR119 agonists, several heterocyclic core systems were introduced as surrogates of the carbamate spacer that mimic the presumed active conformation. This approach successfully produced an indolinylpyrimidine derivative 37, 5-(methylsulfonyl)-1-[6-({1-[3-(propan-2- yl)-1,2,4-oxadiazol-5-yl]piperidin-4-yl}oxy)pyrimidin-4-yl]-2, 3-dihydro-1H-indole, which has potent GPR119 agonist activity. In rat oral glucose tolerance tests, these two indoline-based compounds effectively lowered plasma glucose excursion and glucose-dependent insulin secretion after oral administration.